509 filings
Page 19 of 26
6-K
bn4rv8js
23 Mar 21
Current report (foreign)
5:20pm
6-K
vl077cvz4
23 Mar 21
Current report (foreign)
3:53pm
6-K
d91zy kc0
22 Mar 21
Current report (foreign)
2:50pm
6-K
ik6acq1a3omv m9bmi
22 Mar 21
Current report (foreign)
2:44pm
6-K
4wn kp0ntemlr
22 Mar 21
Current report (foreign)
2:38pm
6-K
babn7 9xb65mia
22 Mar 21
Current report (foreign)
12:42pm
6-K
90p4 cbmk1p
16 Mar 21
MorphoSys AG Presents Results for Full Year 2020
4:34pm
6-K
o3xi1wl0 7wmh8
9 Mar 21
Conference Call Alert
4:14pm
6-K
ulyep9f938109
3 Mar 21
MorphoSys’s Licensing Partner GSK Shared Preliminary Results
6:13am
6-K
61mnbsq
2 Mar 21
Current report (foreign)
7:08am
6-K
8xhwbjaj
26 Jan 21
MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
6:16am
6-K
mchgaoazw5jpfh
13 Jan 21
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
6:09am
6-K
avh8dbkb
12 Jan 21
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
9:54am
6-K
8lvcsbf54r
7 Jan 21
MorphoSys Appoints Sung Lee as Chief Financial Officer
6:14am
6-K
hujhzyl9opane
5 Jan 21
MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
6:11am
6-K
1luvt37c
18 Dec 20
Current report (foreign)
6:09am
6-K
hb212pt
8 Dec 20
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
6:14am
6-K
z3hd8agbys7yz9 zfgb
3 Dec 20
MorphoSys’ Licensee Announces Approval by the European
6:08am
6-K
s8pq8py
2 Dec 20
Thomas Biegi Joins MorphoSys as Head of Corporate Communications
8:37am
6-K
lojob8on0
12 Nov 20
MorphoSys Reports Nine Months and Third Quarter
4:48pm